Back to Search Start Over

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Authors :
Ruperto N
Quartier P
Wulffraat N
Woo P
Loy A
Mouy R
Bader-Meunier B
Prakken B
Noseda E
Rordorf C
Source :
Pediatric Rheumatology Online Journal, Vol 6, Iss Suppl 1, p S2 (2008)
Publication Year :
2008
Publisher :
BMC, 2008.

Details

Language :
English
ISSN :
15460096
Volume :
6
Issue :
Suppl 1
Database :
Directory of Open Access Journals
Journal :
Pediatric Rheumatology Online Journal
Publication Type :
Academic Journal
Accession number :
edsdoj.2c0fcb64a744e60981ea3944e416a11
Document Type :
article
Full Text :
https://doi.org/10.1186/1546-0096-6-S1-S2